Business Context and Reporting Period
ImmunityBio, Inc. (IBRX) is a vertically-integrated commercial-stage biotechnology company focused on developing immunotherapies. The company's primary approved product is ANKTIVA (nogapendekin alfa inbakicept-pmln), an IL-15 receptor superagonist approved by the FDA in April 2024 and the UK MHRA in July 2025 for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). This 10-Q covers the quarterly and six-month periods ended June 30, 2025.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|---|
| Total Revenue | $26,425 | $42,942 | $1,087 |
| Net Loss (Attributable to Common Stockholders) | $(92,555) | $(222,201) | $(268,673) |
| Net Loss Per Share (Basic & Diluted) | $(0.10) | $(0.26) | $(0.40) |
| Cash and Cash Equivalents | $137,658 | $137,658 | $130,104 |
| Marketable Securities | $16,000 | $16,000 | $6,096 |
| Total Current Assets | $208,132 | $208,132 | $184,586 |
| Total Liabilities | $971,895 | $971,895 | $871,062 |
| Stockholders' Deficit | $(569,819) | $(569,819) | $(697,378) |
| Net Cash Used in Operating Activities | N/A | $(165,651) | $(207,329) |
| Net Cash Provided by Financing Activities | N/A | $171,828 | $159,119 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased significantly to $42.9 million for the six months ended June 30, 2025, compared to $1.1 million in the prior year period. This growth is driven by commercial sales of ANKTIVA, which began in May 2024. Product revenue for the quarter ended June 30, 2025, was $26.4 million, a 2,569% increase year-over-year.
- Net Loss Reduction: Net loss attributable to common stockholders decreased to $222.2 million for the six months ended June 30, 2025, from $268.7 million in the prior year period. The reduction is partially attributed to a decrease in interest expense related to related-party debt following a debt extinguishment in December 2024 and favorable changes in the fair value of warrant liabilities.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses decreased by 18% year-over-year for the six-month period, primarily due to lower legal expenses related to litigation settlements. Research and development (R&D) expenses remained relatively flat, decreasing slightly by 1%.
- Financing Activity: The company raised approximately $173.1 million in net proceeds from equity offerings during the first six months of 2025, including an ATM offering and a Registered Direct Offering (RDO) in April 2025.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management states that substantial doubt exists regarding the company's ability to continue as a going concern without additional funding. However, they believe existing cash, marketable securities, product sales, and potential additional financing (including support from the Founder/Executive Chairman) will fund operations for at least the next 12 months.
- Regulatory Developments: In July 2025, the UK MHRA granted marketing authorization for ANKTIVA. Conversely, in May 2025, the FDA issued a "Refuse to File" (RTF) letter regarding the company's supplemental BLA for the papillary-only NMIBC indication, requiring a randomized controlled trial against chemotherapy. The company is evaluating its response strategy.
- Debt Obligations: The company carries significant debt, including a $505 million related-party convertible promissory note (due 2027) and a Revenue Interest Liability of approximately $307 million under the RIPA with Oberland. The RIPA requires quarterly payments based on a percentage of net sales.
- Legal Proceedings: A securities class action lawsuit was settled in June 2025 for $10.5 million (partially covered by insurance). Several shareholder derivative actions were consolidated and preliminarily approved for settlement in July 2025 involving corporate governance reforms. An arbitration with Shenzhen Beike Biotechnology regarding a China license agreement is ongoing.
- Unusual Items: The financial results include significant non-cash adjustments related to the fair value of warrant liabilities, derivative liabilities, and the related-party convertible note. For the six months ended June 30, 2025, the change in fair value of the related-party convertible note resulted in a $41.4 million loss.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $153.7 million in cash and marketable securities against the high burn rate and significant debt service obligations (RIPA payments and related-party note interest).
- RIPA Impact: Assess the impact of the Revenue Interest Purchase Agreement (RIPA) on future cash flows, specifically the tiered revenue interest payments (4.5% to 10.0% of net sales) and the potential "True-Up Payment" obligation if cumulative payments do not meet the threshold by the Test Date (Dec 31, 2029).
- Regulatory Risks: Monitor the resolution of the FDA's RTF letter for the papillary NMIBC indication and the potential requirement for a new randomized trial, which could delay revenue expansion.
- Related-Party Transactions: Review the terms of the $505 million convertible note held by Nant Capital (affiliated with Dr. Soon-Shiong) and the extensive related-party agreements for facilities and services, noting the concentration of control and potential conflicts of interest.
- Supply Chain: Evaluate the ongoing shortage of TICE BCG, which is required for the administration of ANKTIVA, and its potential impact on sales volume and market penetration.